STOCK TITAN
  1. Home
  2. Sec-filings
  3. DFTX
  4. [Form 4] Definium Therapeutics, Inc. Insider Trading Activity

Definium Therapeutics (DFTX) director receives RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Definium Therapeutics director David W. Gryska received equity awards as part of his compensation. He was granted 4,666 restricted stock units, each representing one common share, and now holds 19,900 common shares directly after this grant. The filing also reports a grant of stock options for 19,188 common shares at an exercise price of $24.11 per share, expiring on June 10, 2036.

The restricted stock units and options each vest as to 1/12 of the underlying shares on every monthly anniversary of the grant date. If the company’s first annual meeting after the grant occurs before the first anniversary, any remaining unvested RSUs and options will vest immediately before that meeting, subject to his continued service.

Positive

  • None.

Negative

  • None.
Insider GRYSKA DAVID W
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 19,188 $0.00 --
Grant/Award Common Shares 4,666 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 19,188 shares (Direct, null); Common Shares — 19,900 shares (Direct, null)
Footnotes (1)
  1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
RSU grant 4,666 units Restricted stock units granted to director on June 11, 2026
Shares held after grant 19,900 shares Common shares directly held by director following RSU grant
Stock options granted 19,188 options Stock Option (Right to Buy) granted on June 11, 2026
Option exercise price $24.11 per share Conversion or exercise price for 19,188 stock options
Option expiration June 10, 2036 Expiration date of the granted stock options
Monthly vesting fraction 1/12 per month RSUs and options vest 1/12 each monthly anniversary of grant
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with 19,188 underlying common shares and a $24.11 exercise price"
vests and becomes exercisable financial
"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary"
annual meeting financial
"immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GRYSKA DAVID W
(Last)(First)(Middle)
C/O DEFINIUM THERAPEUTICS, INC.
ONE WORLD TRADE CENTER, SUITE 8500
(Street)
NEW YORK NEW YORK 10007
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Definium Therapeutics, Inc. [ DFTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares06/11/2026A4,666(1)A$019,900D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$24.1106/11/2026A19,188 (2)06/10/2036Common Shares19,188$019,188D
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
2. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
/s/ Mark Sullivan, Attorney-in-Fact for David W Gryska06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did DFTX director David W. Gryska report?

David W. Gryska reported receiving equity awards in Definium Therapeutics. He was granted 4,666 restricted stock units and stock options for 19,188 common shares as compensation, with no open-market buying or selling reported in this Form 4.

How many Definium Therapeutics (DFTX) shares does David W. Gryska hold after this Form 4?

After the transaction, David W. Gryska directly holds 19,900 common shares of Definium Therapeutics. This total reflects his position following the grant of 4,666 restricted stock units reported in the Form 4 filing.

What stock options were granted to David W. Gryska by Definium Therapeutics (DFTX)?

He received stock options covering 19,188 common shares of Definium Therapeutics. These options have an exercise price of $24.11 per share and expire on June 10, 2036, providing long-term potential equity exposure if exercised.

How do David W. Gryska’s restricted stock units in DFTX vest?

The 4,666 restricted stock units vest in 12 equal monthly installments from the grant date. If the company’s next annual meeting occurs before the first anniversary, any unvested units vest immediately before that meeting, subject to his continued service.

What is the vesting schedule for David W. Gryska’s DFTX stock options?

The stock options for 19,188 common shares vest in 12 equal monthly installments from the grant date. If Definium Therapeutics’ next annual meeting occurs before the first anniversary, any unvested options vest immediately before that meeting, assuming he remains in service.

Was David W. Gryska’s DFTX Form 4 a purchase or a compensation grant?

The Form 4 reports compensation-related grants, not open-market purchases. David W. Gryska received restricted stock units and stock options at no cash cost per share on the grant date, categorized as grant or award acquisitions in the filing.